4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 112 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $2,899,000 | +24.4% | 132,117 | +52.9% | 0.04% | +10.5% |
Q3 2021 | $2,331,000 | +150.1% | 86,423 | +123.3% | 0.04% | +123.5% |
Q2 2021 | $932,000 | -75.0% | 38,708 | -54.9% | 0.02% | -79.5% |
Q1 2021 | $3,723,000 | -13.2% | 85,829 | -17.0% | 0.08% | -27.2% |
Q4 2020 | $4,288,000 | – | 103,453 | – | 0.11% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aquilo Capital Management, LLC | 945,382 | $22,765,000 | 5.92% |
Octagon Capital Advisors LP | 831,267 | $20,017,000 | 4.15% |
BVF INC/IL | 2,005,862 | $48,301,000 | 1.81% |
Casdin Capital, LLC | 1,115,555 | $26,863,000 | 0.68% |
Eagle Health Investments LP | 57,090 | $1,375,000 | 0.47% |
Soleus Capital Management, L.P. | 100,800 | $2,427,000 | 0.37% |
VIKING GLOBAL INVESTORS LP | 3,937,914 | $94,825,000 | 0.29% |
ArrowMark Colorado Holdings LLC | 1,029,897 | $24,800,000 | 0.19% |
Perceptive Advisors | 750,512 | $18,072,000 | 0.12% |
Virtus ETF Advisers LLC | 7,642 | $184,000 | 0.08% |